Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy Mole
The platinum-containing chemotherapeutic agents remain key components of many of the most effective regimens for the treatment of cancer. New information about the chemistry, pharmacology and molecular mechanisms by which these drugs work is leading to bo
- PDF / 7,173,984 Bytes
- 380 Pages / 439.37 x 666.142 pts Page_size
- 3 Downloads / 212 Views
Andrea Bonetti • Roberto Leone Franco M. Muggia • Stephen B. Howell Editors
Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy Molecular Mechanisms and Clinical Applications
Editors Andrea Bonetti Department of Oncology Mater Salutis Hospital Legnago Italy [email protected] Roberto Leone University of Verona Institute of Pharmacology Verona, Italy [email protected]
Franco M. Muggia Division of Medical Oncology New York University School of Medicine and the NYU Cancer Institute New York, NY, USA [email protected] Stephen B. Howell Department of Medicine and the Moores Cancer Center University of California, San Diego La Jolla, CA USA [email protected]
ISBN: 978-1-60327-458-6 e-ISBN: 978-1-60327-459-3 DOI: 10.1007/978-1-60327-459-3 Library of Congress Control Number: 2008939849 © Humana Press, a part of Springer Science+Business Media, LLC 2009 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper springer.com
This book is dedicated to the memory of Lloyd R. Kelland, Ph.D., a generous and thoughtful colleague whose careful investigating of the mechanisms by which the platinum-containing drugs kill tumor cells provided valuable insights into how to improve their use in the management of cancer.
Preface
Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broaden
Data Loading...
